Advertise on podcast: JTO Insights

Episode 13: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the October issue of the Journal of Thoracic Oncology. Sai Yendamuri, MD, MBA, FACS, Director of the Thoracic Surgery Research Laboratory at Roswell Park Comprehensive Cancer Center in Buffalo, New York discusses their article Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction; and Mitsuhiro Isaka, MD, PhD, Deputy Chair of the Division of Thoracic Surgery at the Shizuoka Cancer Center in Shizuoka, Japan discusses their article Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L. Recommended Reading: 1. Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction https://www.jto.org/article/S1556-0864(26)00519-8/fulltext 2. Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L https://www.jto.org/article/S1556-0864(26)00369-2/fulltext 3. JTO October 2026: Volume 21, Issue 10 https://www.jto.org/current Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guests: -Sai Yendamuri, MD, MBA, FACS, Chief Strategy Officer, SVP Business Development and Outreach, President and CEO, RPCI Oncology PC, Professor and Chair, Department of Thoracic Surgery, Director, Thoracic Surgery Research Laboratory, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States -Mitsuhiro Isaka, MD, PhD, Deputy Chief, Division of Thoracic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan

In this episode of JTO Insights, recorded at the 2026 World Conference on Lung Cancer, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host the corresponding author of an article published in the JTO 20th Anniversary Series. Dr. Karen Reckamp, Professor of Medicine, Division of Medical Oncology at Cedars Sinai Medical Center, joins us to discuss their article, "The Evolution of Immunotherapy Revolution in Lung Cancer: a 20 Year Perspective." Recommended Reading: 1. The Evolution of Immunotherapy Revolution in Lung Cancer: a 20 Year Perspective: https://www.jto.org/article/S1556-0864(26)00410-7/fulltext 2. JTO 20th Anniversary Series www.jto.org/content/20thAnniversarySeries Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guest: -Karen L. Reckamp, MD, MS, Department of Medicine, Division of Medical Oncology, Cedars Sinai Medical Center, Los Angeles, California

Episode 11: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the September issue of the Journal of Thoracic Oncology. Shun Lu, MD, PhD, Associate editor for the Journal of Thoracic Oncology; Director of Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine discusses their article SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China; and Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine discusses their article Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report. Recommended Reading: -SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China G22 https://www.jto.org/article/S1556-0864(26)00166-8/fulltext -Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report https://www.jto.org/article/S1556-0864(26)00347-3/fulltext -JTO Volume 21, Issue 9 - September 2026 https://www.jto.org/issue/S1556-0864(26)X2009-3 Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guests: -Shun Lu, MD, PhD; Associate editor for the Journal of Thoracic Oncology; Director of Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China -Hidetoshi Hayashi, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai, Osaka, Japan

Episode Summary Episode 10: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host the corresponding author of an article published in the JTO 20th Anniversary Series. Dr. Jean-Louis Pujol, Professor at Montpellier School of Medicine of Montpellier University in France, joins us to discuss their article, "Lung cancer patient advocacy progress and new challenges since 2006". Recommended Reading: 1. Lung cancer patient advocacy progress and new challenges since 2006 https://www.jto.org/article/S1556-0864(26)00345-X/fulltext 2. JTO 20th Anniversary Series https://www.jto.org/content/20thAnniversarySeries Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guest: -Jean-Louis Pujol, MD, PhD, Professor, Montpellier University, Montpellier School of Medicine, Montpellier, France

Episode 9: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John speak with authors of two articles published in the August issue of the Journal of Thoracic Oncology. Michael J. Grant, MD, Assistant Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine in New Haven, Connecticut, discusses “ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.” Christian Rolfo, MD, PhD, Division Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at The James Comprehensive Cancer Center, The Ohio State University, discusses “Molecular Profiling Across 80,000 Patients With Lung Cancer.” Recommended Reading: 1. ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer https://www.jto.org/article/S1556-0864(26)00161-9/fulltext 2. Molecular Profiling Across 80,000 Patients With Lung Cancer https://www.jto.org/article/S1556-0864(26)00148-6/fulltext 3. August 2026, Volume 21, Issue 8 https://www.jto.org/issue/S1556-0864(26)X2007-X Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guests: -Michael J. Grant, MD, Assistant Professor of Medicine in the Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut -Christian Rolfo, MD, PhD, Division Director of Medical Oncology, Associate Director for Early Phase Clinical Trials, The James Comprehensive Cancer Center, The Ohio State University, Ohio, United States

Episode Summary Episode 8: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John highlight two articles published in the JTO 20th Anniversary Series. Dr. David Ryan of Royal Brompton & Harefield Hospitals, London, joins us to discuss their article, "Interventional Radiology and Thoracic Oncology: 20 Years of Innovation". Also featured in this episode is the article “Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective" by Drs. Jeremy Erasmus and Ioannis Vlahos. Recommended Reading: 1. Interventional Radiology and Thoracic Oncology: 20 Years of Innovation: https://www.jto.org/article/S1556-0864(26)00343-6/fulltext 2. Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective: https://www.jto.org/article/S1556-0864(26)00016-X/fulltext 3. JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guest: -David Ryan, MD, Royal Brompton Hospital, London, United Kingdom

Episode 7: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host Dr. Masahiro Torasawa, the corresponding author of "Tumor Inflammation–Associated Neurotoxicity Masquerading as Severe Immune Effector Cell–Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report" published in the Journal of Thoracic Oncology July issue. Also featured in this episode is the article "TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors" by Di Federico et al. Recommended Reading 1. Tumor Inflammation–Associated Neurotoxicity Masquerading as Severe Immune Effector Cell–Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report: https://www.jto.org/article/S1556-0864(26)00102-4/fulltext 2. TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors: https://www.jto.org/article/S1556-0864(26)00063-8/fulltext 3. This month’s issue: https://www.jto.org/issue/S1556-0864(26)X2006-8 Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guest: -Masahiro Torasawa, MD, PhD, Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan

Episode 6: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host the corresponding author of an article published in the JTO 20th Anniversary Series. Dr. Emily Stone, a Conjoint Professor at the UNSW Sydney Faculty of Medicine and a consultant respiratory physician at St Vincent's Hospital, Sydney, joins us to discuss their article "Advances in Diagnosis - Pulmonology". Recommended Reading 1. Advances in Diagnosis – Pulmonology: https://www.jto.org/article/S1556-0864(26)00101-2/fulltext 2. JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guest: -Emily Stone, MBBS, PhD, FRACP, Conjoint Professor, Faculty of Medicine, UNSW; St Vincent’s Hospital, Sydney School of Clinical Medicine, UNSW, Sydney, Australia

Episode 5: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the Journal of Thoracic Oncology June issue. Dr. Natasha B. Leighl, Head of Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre, joins us to discuss their article "Identifying patients with high-risk stage I NSCLC using tumor-informed plasma ctDNA"; and Dr. Gabriella Sozzi, who leads the Experimental Oncology Department and Epigenomics & Biomarkers of Solid Tumors Unit at National Cancer Institute in Milan, Italy, joins to discuss their article, "Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose CT Lung Cancer Screening". Recommended Reading: 1. Identifying patients with high-risk stage I NSCLC using tumor-informed plasma ctDNA: https://www.jto.org/article/S1556-0864(26)00098-5/fulltext 2. Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose CT Lung Cancer Screening: https://www.jto.org/article/S1556-0864(26)00067-5/fulltext 3. This month’s JTO issue: https://www.jto.org/issue/S1556-0864(26)X2004-4 Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guests: -Gabriella Sozzi, PhD, Epigenomics & Biomarkers of Solid Tumors Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy -Natasha B. Leighl, MD, MMSc, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the JTO 20th Anniversary Series. Dr. Stephen Lam, Director of the MDS-Rix Early Lung Cancer Detection and Translational Research Program at BC Cancer Research Institute, joins us to discuss their article, “A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening"; and Dr. Paul Van Schil, Consultant Thoracic Surgeon at Antwerp University Hospital, joins to discuss their article, "Journal of Thoracic Oncology 20th Anniversary Series - Surgery". Recommended Reading: 1. JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries 2. A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening: https://www.jto.org/article/S1556-0864(25)02935-1/fulltext 3. Journal of Thoracic Oncology 20th Anniversary Series - Surgery: https://www.jto.org/article/S1556-0864(25)02938-7/fulltext Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guests: -Paul E. Van Schil, MD, PhD, Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium -Stephen Lam, MD, FRCPC, BC Cancer Research Institute, Vancouver, British Columbia, Canada

Episode 3: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the May issue of the Journal of Thoracic Oncology. Dr. Bonnie Ky, Founder’s Professor of Cardio-Oncology at the Perelman School of Medicine, University of Pennsylvania, discusses their article “Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer”; and Dr. David Planchard, Head of Thoracic Group at Gustave Roussy, discusses their article “Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.” Recommended Reading: 1. Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer: https://www.jto.org/article/S1556-0864(26)00002-X/fulltext 2. Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial: https://www.jto.org/article/S1556-0864(25)03021-7/fulltext 3. JTO May 2026 Issue: https://www.jto.org/issue/S1556-0864(26)X2003-2 Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guests: -David Planchard, MD, Department of Medical Oncology, Thoracic Group, Institut Gustave Roussy, Villejuif, France -Bonnie Ky, MD, MSCE, Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, United States

Episode 2: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the JTO 20th Anniversary Series. Dr. Michele Carbone, Director of the Thoracic Oncology Program at the University of Hawaii Cancer Center, joins us to discuss their article, “Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact"; and Dr. Jeff Bogart, Distinguished Professor and Chair of Radiation Oncology of SUNY Upstate Medical University, New York, joins to discuss their article, "The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress". Recommended Reading: 1. JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries 2. "Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact": https://www.jto.org/article/S1556-0864(25)02895-3/fulltext 3. "The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress": https://www.jto.org/article/S1556-0864(26)00031-6/fulltext Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guests: -Michele Carbone, MD, PhD, Thoracic Oncology Program, University of Hawaii Cancer Center, Hawaii, United States -Jeffrey A. Bogart, MD, SUNY Upstate Medical University, New York, United States

Episode 1: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the Journal of Thoracic Oncology April 2026 issue. Dr. Timothy F. Burns, Professor of Medicine in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, joins us to discuss their article "Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC"; and Dr. Paaladinesh Thavendiranathan of Division of Cardiology, Peter Munk Cardiac Center at the Toronto General Hospital and the Director of the Ted Rogers Program in Cardiotoxicity Prevention joins to discuss their article, "The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapy". Key Topics Covered: • KRAS G12C-mutant NSCLC • Thymoma • Cardiovascular adverse outcomes Recommended Reading: 1. April 2026 JTO Issue: https://www.jto.org/issue/S1556-0864(26)X2002-0 2. "Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC": https://www.jto.org/article/S1556-0864(25)02936-3/fulltext 3. "The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapy": https://www.jto.org/article/S1556-0864(25)02940-5/fulltext Podcast Hosts: -Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology; Chief, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA -Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia Podcast Guests: -Timothy F. Burns, MD, PhD, Professor of Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA -Dinesh Thavendiranathan, MD, SM, FRCPC, Professor of Medicine, Director, Ted Rogers in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto, Canada

Welcome to JTO Insights, the official podcast of the IASLC Journal of Thoracic Oncology (JTO). Hosts Dr. Alex Adjei and Dr. Tom John introduce the new podcast and its mission to deliver concise, accessible insights from the latest JTO research. Each episode features expert discussions with authors, highlighting key studies, clinical implications, and future directions in thoracic oncology. Designed for clinicians, researchers, and healthcare professionals, JTO Insights helps you quickly stay informed on the most impactful advances in the field. Subscribe now so you don’t miss an episode – JTO Insights launces this April 2026 and visit jto.org for full articles and additional research. Co-Hosts: • Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief, Journal of Thoracic Oncology, Chief, Taussig Cancer Institute, Cleveland Clinic, OH, USA • Thomas John, MBBS, PhD, Associate Editor, Journal of Thoracic Oncology, Deputy Director, Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia